Engineered bacteria for augmented in situ tumor vaccination

11Citations
Citations of this article
11Readers
Mendeley users who have this article in their library.

Abstract

In situ tumor vaccination has aroused tremendous interest with its capability for eliciting strong and systemic antitumor immune responses. Unlike traditional cancer vaccines, in situ tumor vaccination avoids the laborious process of tumor antigen identification and can modulate tumor immunosuppressive microenvironment at the same time. In recent years, bacteria have been used as both efficient tumor-targeted delivery vehicles and potent adjuvants. Regarding the rapid development in this area, in this review, we summarize recent advances in the application of bacteria for in situ cancer vaccination. We illustrate the mechanisms of bacteria as both efficient tumor immunogenic cell death inducers and tumor-targeted delivery platforms. Then we comprehensively review the engineering strategies for designing bacteria-based in situ vaccination, including chemical modification, nanotechnology, and genetic engineering. The current dilemma and future directions are discussed at the end of this review.

Cite

CITATION STYLE

APA

Shen, X., Zhu, C., Liu, X., Zheng, H., Wu, Q., Xie, J., … Li, H. (2023, January 5). Engineered bacteria for augmented in situ tumor vaccination. Biomaterials Science. Royal Society of Chemistry. https://doi.org/10.1039/d2bm01593e

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free